Mel Formica, PhD, MBA
Member of the Board and Chief Scientific and Health Policy Advisor
“Pamanicor Health AG, enables me to not only advise our international clients on their business challenges. It also provides me with the opportunity to help them understand the fast-changing Life Sciences and Biopharmaceuticals world including new advanced therapies and therefore, partner with them to create sustainable business transformations that benefit patients all over the globe.”
Dr. Formica is an accomplished healthcare executive with 20+ years of international experience in various leadership roles in the area of Life Sciences and Biopharmaceuticals.
Dr. Formica held academic and numerous global leadership roles in market access, marketing, corporate affairs and commercial development at multinational biopharmaceutical companies in Australia, U.S., China, Japan, Switzerland and Europe. Prior to joining Pamanicor Health AG, Dr. Formica served as Vice President, Head of Global Market Access for five years at Takeda Pharmaceuticals International, the largest Japanese pharmaceutical company. Before that Dr. Formica was six years as Head Value & Access, Corporate Affairs Europe as well as Therapeutic Area Head and Global Payer Lead at Amgen Inc. U.S. and Amgen Europe, one of the biggest biopharmaceuticals companies in the world. Dr. Formica spent several years at Abbott Laboratories as well as worked as a management consultant in the Life Sciences and Biopharmaceutical fields. Dr. Formica has extensive experience with successful global biopharmaceutical product launches, including Humira®, Prolia®, Xgeva®, Entyvio®, Ninlaro®, Adcetris®.
He is the co-founder of the BCG Market Access Roundtable and the London School of Economics and Political Science Market Access Academy.
Dr. Formica brings extensive experience spanning value and evidence generation, clinical research, marketing and strategic consulting with successful global product launches. He is an innovator in integrating novel evidence-based methods to drive efficiencies in medical and commercial data generation, data synthesis and data utilization. A transformation leader, he has pioneered new organizational models leading to improved operating efficiency and driving business growth.
He is primarily focused at the forefront of functional developments in integrated care solutions, market access, pricing and evidence generation including Real World Evidence and policy. Dr. Formica has an excellent track record in market shaping, reforms and restructuring, championing new business and customer engagement models as well as value-added collaborative partnerships. His research interests include osteoporosis and metabolic bone diseases, stem cell and gene therapies, rare diseases, health economics, health technology assessments as well as health policy analysis.
Dr. Formica has held academic and research appointments at the College of Physicians and Surgeons of Columbia University, New York, and both St. Luke’s-Roosevelt Hospital Center and Helen Hayes Hospital, New York. Dr. Formica earned his PhD (Medicine) at the University of Melbourne, Australia. He then completed his post-doctoral training in the Department of Medicine at Columbia University, New York. Dr. Formica also holds an Executive MBA from the Lubin School of Business, New York.